24 results
Thumbnail

D2.437 - Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema

Thumbnail

D2.436 - Application Study on the prevention and treatment of spleen aminopeptide oral solution on seasonal allergic rhinitis

Thumbnail

D2.438 - Adipose-derived stem cells secretome attenuates eosinophilic inflammation in a chronic rhinosinusitis with nasal polyps mouse model

Thumbnail

D2.439 - Low vitamin D levels in patients with allergic rhinitis and its supplementation

Thumbnail

D2.440 - Burden of disease and patient preference in Hereditary Angioedema: findings from a mixed methods survey of carers and patients in the United Kingdom

Thumbnail

D3.34 - Cephalosporine drug provocation in a population of children with confirmed serum sickness-like reaction to amoxicillin

Thumbnail

D3.35 - Severe atopic dermatitis poorly controlled, or something else?

Thumbnail

D3.36 - Contact allergy to sodium metabisulfite in Singapore: A single-center retrospective study of patch test data from 2004 to 2021

Thumbnail

D3.37 - Beware of the Rare: AGEP

Thumbnail

D3.39 - Autoimmune Progesterone Dermatitis Case Report

Thumbnail

D3.42 - Symmetrical drug-related intertriginous and flexural exanthema related to symptomatic slow-acting drug for osteoarthritis (SYSADOA) – a case report

Thumbnail

D3.44 - The Role of Medical History and Diagnostic Testing in Identifying Post-Surgical Allergic Reactions

Thumbnail

D3.45 - Perioperative Immediate Hypersensitivity Reactions: First Chilean Cohort Study 2020-2024 Clinical Hospital University of Chile

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series